Chromatin, Inc. to Address Business, Technology Implications of Plant Science at International BIO Convention

Primary tabs

Chromatin, Inc. to Address Business, Technology Implications of Plant Science at International BIO Convention

CEO, Director of Transgenic Programs to Highlight Successful Partnerships, Next-generation Technologies
tweet me:
Chromatin speaks on next-gen technologies, state of art in Agbiotech alliances w/ #Bayer, #Dow & #Syngenta at #BIO2010 http://3bl.me/ptp9s5

Summary

Chromatin, Inc. announced today that CEO Daphne Preuss and Director of Transgenic Programs Otto Folkerts will speak on the business and technology implications of the company’s work in separate panels at the BIO International Convention 2010, occurring this week at McCormick Place in Chicago, IL.

 

Tuesday, May 4, 2010 - 3:40pm

CONTENT: Press Release


(3BLMedia/theCSRfeed) CHICAGO, IL – May 4, 2010Chromatin, Inc. announced today that CEO Daphne Preuss and Director of Transgenic Programs Otto Folkerts will speak on the business and technology implications of the company’s work in separate panels at the BIO International Convention 2010, occurring this week at McCormick Place in Chicago, IL.  The international convention, hosted by the Biotechnology Industry Organization (BIO), is the largest global event for the biotechnology industry.  

Today, Director of Transgenic Programs Otto Folkerts will participate in a panel entitled: “Next-Generation Technologies – Current State and Outlook.”  The panel will describe how cutting-edge plant transformation and genome modification technologies, including Chromatin’s mini-chromosome technology, are changing the way agricultural crops are developed.  The panel will also cover the current state of technology and when these benefits will be realized in the marketplace.

On Thursday, CEO Daphne Preuss will participate on the panel “Little Big, The State of Art in Agbiotech Alliances.”  The panel will showcase how the recent surge of interest in biotechnology partnerships has both benefited from and contributed to ag-bio advances, especially from leading technology-developing companies like Chromatin.  Preuss will join panelists from current Chromatin alliance partners Dow AgroSciences, Bayer CropScience and Syngenta, along with K&L Gates, and will discuss the structuring of Chromatin’s successful deals with major agricultural companies, pointing out how small companies like Chromatin with big ideas and big companies with investment capital need each other to further ambitious agbiotechnology projects.

Next-Generation Technologies – Current State and Outlook will take place on Tuesday May 4, from 2pm-3:30pm in room N426C of McCormick Place, Chicago.

Little Big, The State of Art in Agbiotech Alliances will take place on Thursday May 6, from 10am to 11:30am in room N426C of McCormick Place, Chicago.

About Chromatin

Chromatin, Inc. is a biotech company developing and marketing innovative technologies and products that benefit the agricultural, energy, chemical, nutritional, and pharmaceutical sectors. Since 2000, the company has successfully developed and commercialized its proprietary gene stacking technology, which can be used to simultaneously, and precisely introduce multiple genes in any plant. Now, by deploying a broad and unique intellectual property platform, Chromatin is developing specialized sorghum feedstocks for the renewables industry. These next generation, high-quality feedstocks are being designed by Chromatin’s elite team of experts to meet the precise yield and performance requirements of the bioprocessing industry. For additional information visit www.chromatininc.com.

 CHROMATIN6470

Keywords: Agbiotech | Bayer | Chromatin | Dow | Syngenta | bio | biotech | feedstocks | renewable energy

CONTENT: Press Release

parse.ly